EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of bacterial ghosts as novel drug delivery systems to improve cancer treatment

Amin Afkhami-Poustchi, Maryam M. Matin

Journal of Cellular Immunotherapy · 2015

DOI: 10.1016/j.jocit.2015.10.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Immunotherapy, 2015. Verfasst von Amin Afkhami-Poustchi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

activation of the c-fos promoter. The c-fos proto-oncogene has been implicated as a regulator of estrogen-mediated cell proliferation. Apoptosis and cell protection: TOX3 was demonstrated to be expressed downstream of a cytoprotective cascade together with CITED1, a transcriptional regulator that does not bind directly to DNA and enhances transcription mediated by diverse transcription factors, such as estrogen receptors, SMAD, or early growth response (EGR) 2. CITED1 expression parallels with estrogen receptors ERa and ERb. TOX3 over-expression protects neuronal cells from cell death caused by endoplasmic reticulum stress or BAX over-expression through the induction of repression of pro-apoptotic transcripts and anti-apoptotic transcripts, which associates with enhanced transcription implicating isolated estrogen-responsive elements (ERE) and estrogen-responsive promoters. TOX3 also interacts with native CREB and induces the CREB-responsive BCL-2 promoter. Coexpression of CITED1 inhibits the CREB-responsive BCL-2 promoter and by contrast, co-expression of CREB inhibits TOX3-mediated transcription from the estrogen-responsive complement C3 promoter. Results have suggested that TOX3 can mediate cytoprotective transcription from the BCL-2 promoter or the complement C3 promoter, based on the predominance of either phosphorylated CREB or CITED1 within the transcriptionally active complex. Regulation of estrogen: TOX3 is also shown to regulate Trefoil Factor Family 1 (TFF1), the estrogen-regulated protein, in an estrogen-independent and tamoxifen-insensitive way. TFF1, a small cysteine-rich secreted protein, is normally expressed at highest levels in the mucosa of the gastrointestinal tract and also is extensively expressed at high levels in malignant breast epithelial cells where its expression is regulated by estrogen. Even in the absence of estrogen, TFF1 was upregulated by TOX3. Additionally, TOX3 induces enhancer RNAs that have been involved in TFF1 gene regulation. FOXA1 and ESR1: It is known that a SNP near its 5ʹend and promoter appears to be strongly associated with breast cancer susceptibility. Breast cancereassociated SNPs are also enriched for FOXA1 and ESR1 transcription factorebinding sites and H3K4me1 histone modification. This SNP alters a FOXA1, a protein required for estrogen receptor-a (ER) function, with disease susceptibility associated with enhanced FOXA1 binding, disordered enhancer function, and a reduce in TOX3 gene expression. The data may offer a validation for prophylactic treatment of high-risk patients with FOXA1 inhibitors. TOX3 and bone metastasis of breast cancer: Some TOX3 expressing tumors are linked with adverse outcome, and increased expression of TOX3 mRNA that has been involved in breast cancer metastatic to bone. In microarray analysis, between the genes upregulated by TOX3 was the well-investigated pro-metastatic gene CXCR4. It has been indicated that IGF-1 cooperates with CXCR4 signaling to advance bone marrow metastasis of breast cancer, potentially one factor in the aggressive behavior of LumB tumors. Since CXCR4 is upregulated by TOX3 and is highly expressed in LumB tumors, this could improve the migratory properties of MCF-7 cells. Therefore, IGF-1 could play a role in regulation of TOX3 expression. MCF-7 cells treated with IGF-1 indicated significant, albeit modest, upregulation of TOX3 expression, as well as the known IGF-1 target gene GAPDH. TOX3 and therapeutic modalities for breast cancer: TOX3 expression is regarded a tumor promoter rather than a tumor suppressor in breast cancer. It has been suggested that TOX3 expression decreases in breast cancer and is correlated with the disease risk. Furthermore, TOX3 has the potential to regulate ER target gene expression in the appearance of limiting concentrations of estrogen. This potential property underlines the treatment modalities for TOX3 breast cancer. It is also suggested that TOX3 and related biomarkers, such as SCUBE2, TFF1, TFF3, AGR2, CEACAM6, TSPAN1 or CXCR4 are helpful for the diagnosis, prognosis and treatment as well as classification of different breast cancer subtypes. Knocking down of TOX3 by siRNA suggests that even low levels of TOX3 may affect estrogen activation of the TFF1 gene. Additionally, estrogen treatment in cells over-expressing TOX3 results in a hyper-responsive TFF1 gene expression. Expression of TOX3 may be implicated in the resistance to endocrine therapy which may occur in some LumB cancers. In this respect, cells over-expressing TOX3 had a better capability to survive under estrogen-deprived conditions. IGF-1 treatment in MCF-7 cells can also cause TOX3 up-regulation. This growth factor has been shown to result in breast cancer development and endocrine resistance during stabilization of FOXA1 protein in MCF-7 cells. Furthermore, FOXA1 alters the pattern of ER binding in poor outcome/metastatic ER breast cancer leading to a situation similar to that in ER good outcome breast cancer. Conclusion: TOX3 gene amplification is associated with reduced risk of the disease and metastasis. TOX3 significantly is associated with increased breast cancer cell proliferation, migration, survival, tumor development. Many studies confirm a key role for TOX3 in breast cancer pathology. However, TOX3 plays dual and conflicting roles in cancer initiation and progression which remains to be investigated.

Zitieren

APA

Afkhami-Poustchi, A., & Matin, M. M. (2015). Use of bacterial ghosts as novel drug delivery systems to improve cancer treatment. Journal of Cellular Immunotherapy. https://doi.org/10.1016/j.jocit.2015.10.009

Vancouver

Afkhami-Poustchi A, Matin MM. Use of bacterial ghosts as novel drug delivery systems to improve cancer treatment. Journal of Cellular Immunotherapy. 2015. doi:10.1016/j.jocit.2015.10.009

BibTeX
@article{AfkhamiPoustchi2015,
  author = {Afkhami-Poustchi, Amin and Matin, Maryam M.},
  title = {Use of bacterial ghosts as novel drug delivery systems to improve cancer treatment},
  journal = {Journal of Cellular Immunotherapy},
  year = {2015},
  doi = {10.1016/j.jocit.2015.10.009}
}
Kostenlos starten →